Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.

× No keyword cloud information.

11 in total

1. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors: Sergio Davì; Alessandro Consolaro; Dinara Guseinova; Angela Pistorio; Nicolino Ruperto; Alberto Martini; Randy Q Cron; Angelo Ravelli
Journal: J Rheumatol Date: 2011-02-01 Impact factor: 4.666

Review 2. Macrophage activation syndrome in juvenile idiopathic arthritis.

Authors: Elisabetta Cortis; Antonella Insalaco
Journal: Acta Paediatr Suppl Date: 2006-07

3. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis.

Authors: A T Y Chan; V Cleeve; T J Daymond
Journal: Postgrad Med J Date: 2002-01 Impact factor: 2.401

4. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.

Authors: M Baghai; D R Osmon; D M Wolk; L E Wold; G J Haidukewych; E L Matteson
Journal: Mayo Clin Proc Date: 2001-06 Impact factor: 7.616

5. Necrotizing fasciitis in children in eastern Ontario: a case-control study.

Authors: T Hsieh; L M Samson; M Jabbour; M H Osmond
Journal: CMAJ Date: 2000-08-22 Impact factor: 8.262

6. Necrotizing fasciitis secondary to chickenpox infection in children.

Authors: Peter Clark; Darin Davidson; Mervyn Letts; Lou Lawton; Ayman Jawadi
Journal: Can J Surg Date: 2003-02 Impact factor: 2.089

Review 7. Macrophage activation syndrome: advances towards understanding pathogenesis.

Authors: Alexei A Grom; Elizabeth D Mellins
Journal: Curr Opin Rheumatol Date: 2010-09 Impact factor: 5.006

Review 8. Safety of tumour necrosis factor-alpha antagonists.

Authors: Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal: Drug Saf Date: 2004 Impact factor: 5.606

9. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors: Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal: Arthritis Res Ther Date: 2005-04-04 Impact factor: 5.156

Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.

1. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Review 2. Macrophage activation syndrome in juvenile idiopathic arthritis.

3. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis.

4. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.

5. Necrotizing fasciitis in children in eastern Ontario: a case-control study.

6. Necrotizing fasciitis secondary to chickenpox infection in children.

Review 7. Macrophage activation syndrome: advances towards understanding pathogenesis.

Review 8. Safety of tumour necrosis factor-alpha antagonists.

9. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

10. Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis.

Review 1. Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg.

Review 2. The Immunology of Macrophage Activation Syndrome.

Review 3. Targeting TNF-α for COVID-19: Recent Advanced and Controversies.